Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients With Active AS • Onset of response to upadacitinib 15 mg QD tx was rapid • AEs similar between upadacitinib and placebo #ACR19 @RheumNow